<?xml version="1.0" encoding="UTF-8" ?><rss version="2.0"><channel><title><![CDATA[Novo Nordisk A/S - Press Releases]]></title><description><![CDATA[Novo Nordisk A/S - Press Releases]]></description><link><![CDATA[http://www.novonordisk.com/]]></link><item><title><![CDATA[Novo Nordisk and Innate Pharma swap product rights]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=45cadd39-2d8c-4d42-9db0-ac81d01824cd&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_and_Innate_Pharma_swap_product_rights]]></link><description><![CDATA[Novo Nordisk A/S and Innate Pharma have reached an agreement by which Innate Pharma is granted development and commercialisation rights to NN1975/IPH 2101 in exchange for EUR 2.5 million upfront payment, milestone payments and royalties on future sales of IPH 2101. In addition, Novo Nordisk receives fully paid-up exclusive rights to NN8555/IPH 2301.]]></description></item><item><title><![CDATA[Data from one-year liraglutide phase 3 study published in The Lancet]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=43036bb9-a4fe-43d3-afdf-e2467b10f3b6&sShowLanguageCode=en-GB&csref=RSS_Data_from_one-year_liraglutide_phase_3_study_published_in_The_Lancet]]></link><description><![CDATA[Data from a 52-week phase 3 study (LEAD™ 3) of liraglutide, a once-daily human GLP-1 analogue, were published today by The Lancet. The study showed that liraglutide, when taken alone, produces statistically significant and sustained improvements in blood sugar control in patients with early type 2 diabetes, as compared with glimepiride, a widely used oral antidiabetic drug.(1) Moreover, the treatment with liraglutide leads to weight loss, reduced systolic blood pressure and lower rates of hypoglycaemia after 52 weeks of treatment.(1)]]></description></item><item><title><![CDATA[Novo Nordisk acquires intellectual property rights from Neose Technologies]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=c7558d50-6b27-4c44-8b21-3d45784b839a&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_acquires_intellectual_property_rights_from_Neose_Technologies]]></link><description><![CDATA[Novo Nordisk today announced that it has signed an agreement to acquire intellectual property rights from Neose Technologies Inc. related to Neose’s proprietary GlycoPEGylation technology. The acquired rights are currently subject to a license from Neose for Novo Nordisk’s development of GlycoPEGylated recombinant blood clotting factors FVIIa, FVIII and FIX. ]]></description></item><item><title><![CDATA[Levemir® demonstrates a 24-hour duration of action and significant weight loss in obese patients – new studies announced]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=8928cf4c-17d3-46d0-ab12-7af84a966a34&sShowLanguageCode=en-GB&csref=RSS_Levemir®_demonstrates_a_24-hour_duration_of_action_and_significant_weight_loss_in_obese_patients_–_new_studies_announced]]></link><description><![CDATA[Rome, Italy – Data released today at the European Association for the Study of Diabetes (EASD) Annual Meeting concludes that Levemir® (insulin detemir [rDNA origin] injection) is a once-daily treatment for diabetes patients after demonstrating a 24-hour duration of action in both type 1 and type 2 diabetes.1,2 Results from two other studies announced today reveal that Levemir® can lead to significant weight loss for insulin-naïve patients with type 2 diabetes3, and provides a similar blood glucose response as glargine with no significant difference in daily average consumption (DACON) or diabetes-related pharmacy costs4. ]]></description></item><item><title><![CDATA[Journalists from China and Spain awarded the Novo Nordisk Media Prize 2008]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=d33caa49-439e-423b-a40d-aa69acad61c3&sShowLanguageCode=en-GB&csref=RSS_Journalists_from_China_and_Spain_awarded_the_Novo_Nordisk_Media_Prize_2008]]></link><description><![CDATA[At a ceremony yesterday, Novo Nordisk presented the journalists Xuemei Zhang from China and Jaume Vilalta i Casas from Spain with the Novo Nordisk Media Prize 2008 for the best article and the best TV feature about diabetes, respectively.]]></description></item><item><title><![CDATA[Significant improvement in glycaemic control observed with NovoMix® 30 in type 2 diabetes patients new to insulin]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=be1ce27e-1136-401f-938d-1e06027eb9b9&sShowLanguageCode=en-GB&csref=RSS_Significant_improvement_in_glycaemic_control_observed_with_NovoMix®_30_in_type_2_diabetes_patients_new_to_insulin]]></link><description><![CDATA[Rome, Italy – New data from IMPROVE™ - the largest ever observational study in diabetes – announced today at the European Association for the Study of Diabetes (EASD) Annual Meeting, have shown that treatment with premixed modern insulin NovoMix® 30 resulted in a significant 2.4 percentage point reduction in HbA1c levels in insulin-naïve patients.1 In patients who had previously received no pharmaceutical therapy, the improvement was even more pronounced, with a reduction of 3.2 percentage points. ]]></description></item><item><title><![CDATA[Nine out of 10 children with diabetes lack support at school]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=817d8419-3771-4a29-b020-d875776b8624&sShowLanguageCode=en-GB&csref=RSS_Nine_out_of_10_children_with_diabetes_lack_support_at_school]]></link><description><![CDATA[Rome, Italy – Novo Nordisk, together with the International Society for Pediatric and Adolescent Diabetes (ISPAD), today presented the results from the largest international survey exploring the psychosocial aspects of childhood diabetes. The DAWN Youth (Diabetes, Attitudes, Wishes and Needs) survey draws an alarming portrait of the various challenges that children with diabetes face at school:]]></description></item><item><title><![CDATA[New data from a phase 3 study confirms clinical benefits of once-daily liraglutide in the management of type 2 diabetes]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=30aae397-6bcb-4974-8b89-52a1663bc4ba&sShowLanguageCode=en-GB&csref=RSS_New_data_from_a_phase_3_study_confirms_clinical_benefits_of_once-daily_liraglutide_in_the_management_of_type_2_diabetes]]></link><description><![CDATA[Rome, Italy – Data from a phase 3 clinical study (LEAD™ 4) presented today at the 44th Annual Meeting of the European Association for the Study of Diabetes (EASD) demonstrated that adding the investigational new drug liraglutide, a human GLP-1 analogue, to metformin and rosiglitazone in the treatment of type 2 diabetes, leads to improved blood glucose lowering (HbA1c)1, weight loss, blood pressure reduction and improvement in beta cell functioning.  ]]></description></item><item><title><![CDATA[Novo Nordisk launches a next generation of FlexPen® – the world’s most widely used prefilled insulin pen(1)]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=f920332d-38c3-4f2a-8399-3a4615cbf431&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_launches_a_next_generation_of_FlexPen®_–_the_world’s_most_widely_used_prefilled_insulin_pen1]]></link><description><![CDATA[Rome, Italy – Novo Nordisk announced the launch of a next generation of FlexPen® at the European Association for the Study of Diabetes (EASD) Annual Meeting. The new insulin injection device builds upon the high standards set by the current version of FlexPen®, with new features providing improved safety, convenience and ease of use for people with diabetes. FlexPen® is already the most widely used prefilled insulin device in the world1, benefiting millions of people with diabetes worldwide. ]]></description></item><item><title><![CDATA[Novo Nordisk joins the Call to Action for gender equality]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=14121f25-3fd3-4adf-bb85-141027389ec2&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_joins_the_Call_to_Action_for_gender_equality]]></link><description><![CDATA[Yesterday, the Danish Minister for Development Cooperation Ms Ulla Tørnæs handed over a torch to Executive Vice President Lise Kingo, Novo Nordisk, at a ceremony in Copenhagen. With the torch Ms Tørnæs makes a Call to Action to leaders from around the world to help accelerate progress on the Millennium Development Goal 3 (MDG3): To empower women and promote gender equality.]]></description></item><item><title><![CDATA[Novo Nordisk employee suspended after being charged with insider trading]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=8723b710-7078-4851-99ab-75b81e82a7c9&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_employee_suspended_after_being_charged_with_insider_trading]]></link><description><![CDATA[Novo Nordisk announced today that it has suspended one of its employees after the employee yesterday was charged by the Danish Public Prosecutor for Serious Economic Crime with unlawful insider trading in the company’s shares.]]></description></item><item><title><![CDATA[Clinical study shows liraglutide reduced blood sugar, weight and blood pressure in patients with type 2 diabetes]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=4cb24c3c-167a-4531-aa4e-f669be238917&sShowLanguageCode=en-GB&csref=RSS_Clinical_study_shows_liraglutide_reduced_blood_sugar_weight_and_blood_pressure_in_patients_with_type_2_diabetes]]></link><description><![CDATA[Phase 3 data highlight sustained efficacy and benefits of early treatment with liraglutide versus glimepiride]]></description></item><item><title><![CDATA[Over 70% of patients reach target with NovoMix® 30 in largest ever diabetes study]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=3a3924d1-81d3-44c9-a48e-db229ef6ad9a&sShowLanguageCode=en-GB&csref=RSS_Over_70%_of_patients_reach_target_with_NovoMix®_30_in_largest_ever_diabetes_study]]></link><description><![CDATA[[San Francisco, USA] - New data from the IMPROVE™ study show that significant improvements in glycaemic (blood sugar) control can be achieved with premixed modern insulin, NovoMix® 30, in patients poorly controlled on other, or no previous pharmaceutical treatment. The results were announced over the weekend at the 68th annual meeting of the American Diabetes Association (ADA) in San Francisco. ]]></description></item><item><title><![CDATA[New data from head-to-head study confirms once-daily Levemir® is as effective as glargine over a 24-hour period in subjects with type 2 diabetes]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=ea49c83b-ff9b-4f41-87a2-40b11452cbd5&sShowLanguageCode=en-GB&csref=RSS_New_data_from_head-to-head_study_confirms_once-daily_Levemir®_is_as_effective_as_glargine_over_a_24-hour_period_in_subjects_with_type_2_diabetes]]></link><description><![CDATA[San Francisco – A head-to-head study announced over the weekend at the American Diabetes Association (ADA) meeting demonstrated that Levemir® (insulin detemir [rDNA origin] injection) can be used once daily and had a comparable blood glucose response to insulin glargine over a 24-hour period in patients with type 2 diabetes.]]></description></item><item><title><![CDATA[Novo Nordisk and Neose announce completion of initial phase 1 clinical trial of NN7128 (long-acting factor VIIa)]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=33615eca-c71c-44f2-abdc-8e513f6032ef&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_and_Neose_announce_completion_of_initial_phase_1_clinical_trial_of_NN7128_long-acting_factor_VIIa]]></link><description><![CDATA[COPENHAGEN, Denmark, and HORSHAM, PA — Novo Nordisk A/S (NYSE:NVO) and Neose Technologies, Inc. (Nasdaq GM: NTEC) today announced that Novo Nordisk has completed the initial phase 1 clinical trial with NN7128 (GlycoPEGylated factor VIIa), a long-acting version of NovoSeven® coagulation factor FVIIa (recombinant) administered intravenously. The trial assessed the safety and pharmacokinetics of NN7128 in 30 healthy subjects.  ]]></description></item><item><title><![CDATA[New studies show FlexPen® superiority to SoloStar® in dose accuracy]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=71c30a29-e1e9-4543-a624-c442a9ca9a75&sShowLanguageCode=en-GB&csref=RSS_New_studies_show_FlexPen®_superiority_to_SoloStar®_in_dose_accuracy]]></link><description><![CDATA[Two independent studies show that FlexPen® is more accurate when delivering insulin than other pens like the newly launched prefilled device, SoloStar®, from Sanofi-Aventis, which FlexPen® significantly outperformed in both studies.]]></description></item><item><title><![CDATA[Novo Nordisk researchers nominated for Europe’s top innovation prize]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=693b55e0-7076-4ac3-9d25-2def0c8b6ef9&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_researchers_nominated_for_Europe’s_top_innovation_prize]]></link><description><![CDATA[A team of researchers from Novo Nordisk is nominated for Europe’s top innovation prize, Inventor of the Year 2008 Award, that will be presented at a ceremony in Ljubljana, Slovenia, on 6 May by the European Patent Office and the European Commission.]]></description></item><item><title><![CDATA[Novo Nordisk donation aids Chinese pharmaceutical development and WHO efforts to combat neglected diseases]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=b07d2357-fb41-4298-a093-c5797ddc4724&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_donation_aids_Chinese_pharmaceutical_development_and_WHO_efforts_to_combat_neglected_diseases]]></link><description><![CDATA[Novo Nordisk today announced a scientific collaboration that will benefit both Chinese pharmaceutical development and WHO efforts to combat neglected diseases. ]]></description></item><item><title><![CDATA[Novo Nordisk wins design award for NovoFine® Autocover®]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=6aed1467-f2a0-4798-a704-0d2fb6f20d37&sShowLanguageCode=en-GB&csref=RSS_Novo_Nordisk_wins_design_award_for_NovoFine®_Autocover®]]></link><description><![CDATA[Novo Nordisk has been awarded a 2008 Medical Design Excellence Award for NovoFine® Autocover® – a needle for insulin injection designed especially to reduce the risk of needle stick injuries and help people with diabetes who suffer from needle anxiety.]]></description></item><item><title><![CDATA[TransTech Pharma, Inc. Acquires Three Programs for the Treatment of Metabolic Disorders from Novo Nordisk]]></title><link><![CDATA[http://www.novonordisk.com/press/sea/sea.asp?NewsTypeGuid=&sShowNewsItemGUID=df15fa4c-99b3-46d9-bf86-f1296b070d4f&sShowLanguageCode=en-GB&csref=RSS_TransTech_Pharma_Inc._Acquires_Three_Programs_for_the_Treatment_of_Metabolic_Disorders_from_Novo_Nordisk]]></link><description><![CDATA[High Point, NC, US, and Bagsværd, Denmark – TransTech Pharma, Inc. and Novo Nordisk A/S announced today that TransTech has acquired all rights from Novo Nordisk to a portfolio of drug candidates being developed to treat metabolic disorders. This portfolio is comprised of three distinct therapeutic approaches to such treatment: H3 receptor antagonists, PPARδ agonists and 11βHSD1 inhibitors.]]></description></item></channel></rss>